Clostridioides difficile: Modern Approaches in Pathogenesis, Diagnosis, Treatment, Prevention, Emerging Perspectives and Health Economics
Gastroenterology Insights · 13.04.2026 · 17 (2) · 25
DOI: 10.3390/gastroent17020025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterology Insights, online erschienen am 13.04.2026. Verfasst von Nikoletta T. Karavasili und 9 weiteren Autor:innen. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Clostridioides difficile (C. difficile) is a major cause of antibiotic-associated diarrhea and healthcare-associated infections, with rising global incidence and severity due to the emergence of hypervirulent strains.
Methods
This review synthesizes recent literature on the epidemiology, pathogenesis, diagnostic approaches, and therapeutic strategies related to C. difficile infection (CDI). Sources were selected from peer-reviewed journals, clinical guidelines, and emerging research between 2020 and 2025.
Results
Advances in molecular diagnostics have improved the accuracy and speed of CDI detection. New therapeutic options such as fidaxomicin offer narrower-spectrum antibiotic activity with reduced recurrence rates. Fecal microbiota transplantation (FMT) has emerged as a highly effective option for recurrent CDI. Preventive efforts, including antibiotic stewardship programs and early-phase vaccine trials, show potential in reducing infection rates.
Discussion
The management of CDI is evolving rapidly with the integration of precision diagnostics, targeted therapies, and microbiome-based interventions. Preventive strategies are critical, particularly in healthcare settings where C. difficile persists in the environment. Continued research and coordinated public health efforts are essential to reduce disease burden, improve outcomes, and limit transmission.
Conclusions
Clostridioides difficile infections remain a major healthcare challenge with rising incidence and recurrent cases. Fidaxomicin has become the preferred first-line therapy. Microbiota-based therapies (like FMT, Rebyota, and Vowst) and Lipopolysaccharide Binding Protein (LBP) are highly effective for recurrent CDI prevention. Diagnostic strategies have improved with multi-step testing, enhancing accuracy and reducing overtreatment. Future focus lies in vaccines, targeted antimicrobials, and stricter prevention through antibiotic stewardship and hygiene.
Zitieren
APA
Karavasili, N. T., Katsanos, K. H., Mastorogianni, I. N., Christodoulou, M. V., Manomenidis, G., Kosmidis, D., Tzenalis, A., Eleni, A., Tsiara, S., & Christodoulou, D. K. (2026). Clostridioides difficile: Modern Approaches in Pathogenesis, Diagnosis, Treatment, Prevention, Emerging Perspectives and Health Economics. Gastroenterology Insights, 17(2), 25. https://doi.org/10.3390/gastroent17020025
Vancouver
Karavasili NT, Katsanos KH, Mastorogianni IN, Christodoulou MV, Manomenidis G, Kosmidis D, et al. Clostridioides difficile: Modern Approaches in Pathogenesis, Diagnosis, Treatment, Prevention, Emerging Perspectives and Health Economics. Gastroenterology Insights. 2026;17(2):25. doi:10.3390/gastroent17020025
BibTeX
@article{Karavasili2026,
author = {Karavasili, Nikoletta T. and Katsanos, Konstantinos H. and Mastorogianni, Ioanna Nefeli and Christodoulou, Maria Veatriki and Manomenidis, Georgios and Kosmidis, Dimitrios and Tzenalis, Anastasios and Eleni, Albani and Tsiara, Stavroula and Christodoulou, Dimitrios K.},
title = {Clostridioides difficile: Modern Approaches in Pathogenesis, Diagnosis, Treatment, Prevention, Emerging Perspectives and Health Economics},
journal = {Gastroenterology Insights},
year = {2026},
volume = {17},
number = {2},
pages = {25},
doi = {10.3390/gastroent17020025}
}
EUVIMED